Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

'Give RSV drug to highest risk toddlers'

Under-twos at highest risk of respiratory syncytial virus (RSV) should be given the monoclonal antibody palivizumab, Government vaccine advisers have agreed.

The Joint Committee on Vaccination and Immunisation has recommended all under-twos with severe chronic lung disease on home oxygen during the RSV season are given the monoclonal antibody.

Prescribing the drug was likely to reduce hospital admissions in the group by 39 per cent and be cost neutral to the NHS, the committee said at its last meeting. It is also considering extending the drug's use in children who are not on home oxygen.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say